FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 Inhibitors

Leukemia - United Kingdom
doi 10.1038/leu.2015.165
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The N676D and G697R Mutations in the Kinase Domain of FLT3 Confer Resistance to the Inhibitor AC220

Haematologica
Hematology
2012English

Small Molecule FLT3 Tyrosine Kinase Inhibitors

2012English

Targeting Oncoprotein Stability Overcomes Drug Resistance Caused by FLT3 Kinase Domain Mutations

PLoS ONE
Multidisciplinary
2014English

FLT3 Mutations in Canine Acute Lymphocytic Leukemia

BMC Cancer
Cancer ResearchOncologyGenetics
2011English

Detection of FLT3 Internal Tandem Duplication and D835 Mutations by a Multiplex Polymerase Chain Reaction and Capillary Electrophoresis Assay

Journal of Molecular Diagnostics
Forensic MedicinePathologyMolecular Medicine
2003English

Differential Signaling of Flt3 Activating Mutations in Acute Myeloid Leukemia: A Working Model

Protein & Cell
BiochemistryBiotechnologyDrug DiscoveryCell BiologyMedicine
2011English

FLT3 Inhibitors in the Treatment of Acute Myeloid Leukemia

Cancer
Cancer ResearchOncology
2011English

Overcoming AC220 Resistance of FLT3-ITD by SAR302503

Blood Cancer Journal
OncologyHematology
2013English

Kinase Domain Mutations Confer Resistance to Novel Inhibitors Targeting JAK2V617F in Myeloproliferative Neoplasms

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy